Reduction of Long-Term Opioid Prescribing for Back Pain in Community Health Centers After a Medicaid Policy Change

John Muench, MD, MPH, Megan Hoopes, MPH, Meghan Mayhew, MPH, Maura Pisciotta, MS, Susan M. Shortreed, PhD, Catherine J. Livingston, MD, MPH, Michael Von Korff, ScD, and Lynn L. DeBar, PhD, MPH

Introduction: Beginning around 2011, innumerable policies have aimed to improve pain treatment while minimizing harms from excessive use of opioids. It is not known whether changing insurance coverage for specific conditions is an effective strategy. We describe and assess the effect of an innovative Oregon Medicaid back/neck pain coverage policy on opioid prescribing patterns.

Methods: This retrospective cohort study uses electronic health record data from a network of community health centers (CHCs) in Oregon to analyze prescription opioid dose changes among patients on long-term opioid treatment (LOT) affected by the policy.

Results: Of the 1,789 patients on LOT at baseline, 41.6% had an average daily dose of <20 morphine milligram equivalents (MME), 32.3% had \geq 20 to <50 MME, 14.5% had \geq 50 to <90 MME, and 11.6% \geq 90 MME. Around half of each group discontinued opioids within the 18-month policy period. Those who discontinued did so gradually (average of 11 months) regardless of starting dosage. Predictors of discontinuation included: diagnosis of opioid use disorder, older, non-Hispanic white, and less medical complexity.

Conclusions: Regardless of starting opioid dose, nearly half of patients affected by the 2016 Oregon Medicaid back/neck pain treatment policy no longer received opioid prescriptions by the end of the 18-month study period; another 30% decreased their dose. Gradual dose reduction was typical. These outcomes suggest that the policy impacted opioid prescribing. Understanding patient experiences resulting from such policies could help clinicians and policy makers navigate the complex balance between potential harms and benefits of LOT. (J Am Board Fam Med 2022;35:352-369.)

Keywords: Chronic Pain, Community Health Centers, Health Policy, Medicaid, Opioids, Oregon, Physician's Practice Patterns, Prescriptions, Primary Health Care, Retrospective Studies

Introduction

The U.S. problem with opioid-related morbidity and mortality has been well documented.¹⁻³ It

was initially driven by opioid prescriptions from medical settings, with nearly half generated in primary care clinics.^{4,5} Although opioid prescribing has steadily declined since 2011, prescription rates remain historically high.⁶ Many policies have been implemented at federal, state, and local levels aimed at promoting safer and more efficacious prescribing of opioids. 7-9

This article was externally peer reviewed. *Submitted* 16 July 2021; revised 25 September 2021; accepted 29 September 2021.

From the Oregon Health & Science University, Portland, OR (JM); OCHIN, Inc., Portland, OR (MH and MP); Kaiser Permanente Center for Health Research, Portland, OR (MM, SMS, MVK, and LLD); and Oregon Health & Science University, Portland, OR (CJL).

Funding: This work was supported through a PCORI Project Program Award (UOP-1609-36568).

Conflicting and competing interests: Dr. Livingston previously served as the Associate Medical Director of the Health Evidence Review Commission. She is currently employed as the Medical Director of Health Share of Oregon. This potential conflict of interest has been reviewed and managed by Oregon Health & Science University.

Dr. Shortreed has been a co-Investigator on Kaiser Permanente Washington Health Research Institute (KPWHRI) projects funded by Syneos Health, that is representing a consortium of pharmaceutical companies carrying out FDA-mandated studies regarding the safety of extended-release opioids.

Corresponding author: John Muench, MD, MPH, Department of Family Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mail Code FM, Portland, OR 97239 (E-mail: muenchj@ohsu.edu).

A unique opioid policy was implemented in Oregon in 2016. The state's Medicaid program is provided through the Oregon Health Plan (OHP). Using evidence synthesized by the state Health Evidence Review Commission,^{10,11} the OHP instituted 2 coverage guidelines that aimed to improve access to safer, nonpharmacologic evidence-based treatments while concurrently limiting payments for long-term opioid therapy (LOT) and other interventional approaches for back and neck pain.^{12,13}

These changes were intended to be implemented step-wise over an 18-month period starting in July 2016 when the OHP began reimbursing nonpharmacological treatments, such as acupuncture, massage, and physical therapy, for back and neck pain (see Figure 1). In January 2017, clinicians were expected to establish a taper plan for patients on LOT; by January 2018 coverage of opioids for back and neck pain was restricted to a 90-day limit with the intent of ending long-term opioid treatment for back and neck pain at that time.

Unfortunately, little is known about how such an insurance payment policy might affect patient opioid use over time and particularly, what was the experience of patients on LOT. Prior experience suggests it is hard to taper patients who have been on opioids long-term, especially those on higher doses.^{14,15} While there is general agreement that opioids have been overprescribed in the U.S., recent literature has raised questions about potential harms


Figure 1. Timeline of Oregon policy implementation.

of inappropriate forced reductions or tapering too rapidly. $^{16\mathchar`20}$

Community health centers (CHCs) are clinics that serve predominantly low-income patients by reducing barriers to treatment such as cost. A large proportion of patients seen at CHCs are Medicaid beneficiaries who were impacted by the Oregon policy changes described above.²¹ Using electronic health record (EHR) data from a large network of CHCs in Oregon, we retrospectively evaluated a cohort of patients with Medicaid insurance on LOT with back and neck pain at the time the OHP guidelines went into effect (July 2016) to measure the extent to which patients were able to taper or discontinue use of opioids by the January 1, 2018 date of payment restriction. In addition, we assessed how rapidly those dose reductions took place, and differences in discontinuation rates by important sociodemographic and clinical characteristics. This study is part of a larger mixed-methods research project evaluating the impact of the Oregon Medicaid treatment reimbursement policy using a natural experiment design.²²

Methods

We conducted a retrospective cohort study using EHR data from OCHIN, a nonprofit community health information network providing a linked,



¹Acupuncture, chiropractic manipulation, osteopathic manipulation, physical therapy, occupational therapy, cognitive behavioral therapy; and, if available, yoga, massage, supervised exercise therapy, intensive interdisciplinary rehabilitation

hosted EHR to >1,000 CHC sites across 22 states. These data are part of the Accelerating Data Value Across a National Community Health Center (ADVANCE) Clinical Research Network (CRN), a member of PCORnet. At the time of the study, OCHIN represented approximately 70% of the CHCs in Oregon, and these CHCs provided care to an estimated 20% of all statewide Medicaid enrollees. To approximate the policy's target population from EHR data, we identified a cohort of Oregon patients aged 18 to 64 with at least 1 Medicaid-insured visit and recorded diagnosis codes for back or neck pain documented in the baseline 12 months before July 1, 2016. We then "followed" this group in the EHR data for an 18month study period, ending December 31, 2017. Inclusion criteria included having at least 1 office visit in the study period.

Patients on LOT were identified by being prescribed at least 60 pills or tablets of opioid pain medication or any fentanyl patch in each of the 2 calendar quarters before baseline (January 1, 2016– March 31, 2016 and April 1, 2016–June 30, 2016). We excluded patients with documentation of cancer or palliative care at any point in the study period, as these enrollees were excluded from the opioid reduction policy.

The eligible patient population at baseline was described demographically (sex, age, race/ethnicity) and clinically (annual visit rate, documented substance use disorders, and mood disorders). We used the Charlson Comorbidity Index²³ as an aggregate measure of medical complexity at baseline, and counted the number of pain conditions in addition to back and/or neck pain in accordance with meaningful pain condition categories established by the National Pain Strategy Epidemiologic Working Group.²⁴ All conditions were assessed from diagnosis codes recorded on patients' EHR problem lists at baseline; back and neck pain diagnoses used for study inclusion were additionally ascertained from diagnoses recorded in encounters. Problem lists are actively maintained by clinicians in this CHC network, with noted and inactive dates allowing us to ascertain conditions that were "active" for each patient at different timepoints. Condition definitions are presented in Appendix Table 1.

We pulled all opioid prescribing data recorded in the EHR from July 1, 2016 through December 31, 2017 to assess tapering and discontinuation corresponding to the expected interval for tapering affected patients off LOT. Morphine milligram equivalents (MME) were calculated using standard methods and conversion factors.²⁵ To estimate average daily MME at baseline we summed total MME prescribed for the period January 1, 2016–June 30, 2016 (the 2 quarters used to assess LOT status) and divided by 181 days. To estimate average daily MME throughout the follow-up period we summed total MME per quarter, for each of the 6 follow-up quarters, and divided by 90 days.

We categorized patients on LOT into 4 groups for analysis based on average daily MME at baseline: less than 20 MME, 20 or more and less than 50 MME, 50 or more and less than 90 MME, and at least 90 MME. At the study's end point, we described the percentage of each group who discontinued (ie, had 0 MME prescribed in last quarter or earlier), had a partial reduction in MME (ie, last quarter MME less than baseline MME), or had no reduction in MME (ie, last quarter MME equal to or greater than baseline MME). To describe patterns of reduction, we calculated median average daily dosages with interquartile ranges for each study quarter and, for those who completely tapered, the mean number of quarters to achieve 0 MME.

Finally, we estimated crude and adjusted odds ratios (aOR) of discontinuing opioid use by all demographic and clinical variables described above.

Although CHC utilization was not a primary outcome, number of visits is likely related to opioid prescribing and reduction outcomes. Thus, we also examined annual visit rates during the 18-month observation period stratified by ending dose and, for patients who fully discontinued opioid use, described visits that occurred after their last opioid prescription (Appendix Table 2). A sensitivity analysis was conducted by excluding patients who appeared to have discontinued opioid use but did not return for a follow-up visit in the study period following their last opioid prescription date (Appendix Tables 3-T4).

Statistical significance was set at P < .05. Data management and analysis were conducted using SAS (v9.4; SAS Institute Inc., Cary, North Carolina). This project was approved by the Kaiser Permanente Washington Institutional Review Board.

Results

Among the total cohort of LOT patients at baseline (n = 1789), 745 (41.6%) had an average daily dose

less than 20 MME, 578 (32.3%) were between 20 and 50 MME, 259 (14.5%) were between 50 and 90 MME, and 207 (11.6%) were on baseline doses of at least 90 MME (Table 1). The sample was predominantly female (60.5%) and non-Hispanic white (87.0%), with a mean age of 49.2. The cohort had a high level of medical complexity (32.5% had baseline Charlson Comorbidity Index scores \geq 3; 61.4% had a diagnosed mood disorder). Patients were also high utilizers of these CHC clinics, having a median of 9 ambulatory visits in the year before the policy introduction.

Across the entire cohort, 47.9% demonstrated discontinuation of opioid use by the end of the 18-month policy period; another 30.0% reduced their daily MME dose and 20.3% experienced no reduction in dose (Table 2). Similar patterns were seen when stratified by baseline dose: 52.6% of the lowest dosage group (less than 20 MME) reduced to 0 MME, as did 47.4% of those starting between 20 and 50 MME, 48.3% of the between 50 and 90 MME group, and 47.3% of the highest dosage (at least 90 MME) group. Among the highest-dose group at baseline, only 44 patients (21.3%) remained on doses of at least 90 MME at the end of follow-up, and only 13 of these patients (6.3%) had no reduction in their average daily opioid dose. Other groups experienced similar reduction to safer doses, even among those who did not fully taper.

Patients who discontinued opioid use tapered to zero across an average of 3.6 calendar quarters (or about 11 months; Table 2); the highest dose group at baseline (at least 90 MME) tapered more slowly (mean = 4.1 quarters, or about 12 months) than groups with lower baseline doses. Gradual tapering was evident across all groups, regardless of starting or ending dosage (Figure 2).

Patients on the highest opioid doses at the end of follow-up had higher CHC utilization during the study period than their lower-dose counterparts, but all groups continued to have high visit rates throughout the observation period (at least 4.7 visits per year on average, Appendix Table 2). Among patients who discontinued opioid use, 64% of them returned for 1 or more visits after their last opioid prescription. When limiting to patients who returned for ≥ 1 visit after their last opioid prescription (sensitivity population), a smaller proportion was observed to discontinue opioid use (38.6%), 36.6% had a partial reduction, and 24.9% had no reduction in MME (Appendix Table 4). Baseline

Table 1. Baseline Characteristics of Oregon MedicaidPatients with Back or Neck Pain on Long-Term OpioidTherapy

	n (%)
	N = 1,789
Sex	
Female	1083 (60.5)
Age, years	
Mean (SD)	49.2 (9.2)
19 to 34	163 (9.1)
35 to 49	593 (33.2)
50 to 64	1033 (57.7)
Race/ethnicity	
Non-Hispanic White	1556 (87.0)
Hispanic, Black, Indigenous, other patients of color, and unknown race/ethnicity	233 (13.0)
Eligible pain diagnoses	
Back pain	1183 (66.1)
Neck pain	223 (12.5)
Both	383 (21.4)
Average daily MME	
<20	745 (41.6)
20 to <50	578 (32.3)
50 to <90	259 (14.5)
≥90	207 (11.6)
Number of visits in the prior year	
Median (IQR)	9.0 (6.0, 14.0)
<6	422 (23.6)
6 to 9	523 (29.2)
10 to 12	305 (17.1)
>12	539 (30.1)
Charlson Comorbidity Index*	
0	309 (17.3)
1 to 2	899 (50.3)
≥3	581 (32.5)
N pain clusters (of 8)* [†]	
0	338 (18.9)
1	638 (35.7)
≥2	813 (45.4)
Alcohol abuse/dependence*	164 (9.2)
Opioid abuse/dependence*	80 (4.5)
Other drug abuse/dependence*	224 (12.5)
Mood disorder* [‡]	1098 (61.4)

Abbreviations: SD, standard deviation; MME, morphine milligram equivalence; IQR, interquartile range.

*Conditions based on active problem list entries at baseline. [†]Pain conditions assessed: (1) limb/extremity pain, joint pain, and arthritic disorders; (2) neuropathic pain conditions; (3) headache; (4) abdominal and bowel pain; (5) urogenital, pelvic, and menstrual pain; (6) musculoskeletal chest pain; (7) systemic disorders or diseases causing pain; (8) orofacial, ear, and temporomandibular disorder pain. See Appendix Table 1 for definitions.

[‡]Includes depression and anxiety disorders. See Appendix Table 1 for definitions.

		Average daily dose at baseline			
	Total N = 1,789 n (column %)	<20 MME N = 745 column %	20 to < 50 MME N = 578 column %	50 to <90 MME N = 259 column %	≥90 MME N = 207 column %
Opioid reduction measures at end of follow-v	ıp				
Reduced to 0 MME	889 (47.9%)	52.6%	47.4%	48.3%	47.3%
Mean (SD) number of calendar quarters to reduce to zero MME	3.6 (1.6)	3.0 (1.6)	3.4 (1.7)	3.9 (1.5)	4.1 (1.4)
Partially reduced MME	536 (30.0%)	24.0%	31.1%	31.3%	46.4%
Mean (SD) MME at end of follow-up, among patients with partial reduction	28.0 (33.5)	7.4 (4.5)	18.9 (10.1)	36.3 (18.9)	76.4 (49.1)
Did not reduce MME	364 (20.3%)	23.4%	21.5%	20.5%	6.3%
Average daily dose at end of follow-up					
0 MME	889 (49.7%)	52.6%	47.4%	48.3%	47.3%
1 to <20 MME	415 (23.2%)	39.5%	16.1%	7.7%	3.9%
20 to <50 MME	287 (16.0%)	6.6%	31.1%	13.9%	10.6%
50 to <90 MME	133 (7.4%)	1.1%	5.0%	23.6%	16.9%
≥90 MME	65 (3.6%)	$<\!1\%^{\pm}$	$< 1\%^{\pm}$	6.6%	21.3%

 Table 2. Opioid Reduction Outcomes Among Oregon Medicaid Patients with Back or Neck Pain on Long-Term

 Opioid Therapy, by Baseline Dose


Abbreviations: MME, morphine milligram equivalence; SD, standard deviation.

Patient Ns have been suppressed in this table due to some small cell sizes.

demographics and opioid reduction outcomes by starting dose followed similar patterns to the full sample (Appendix Tables 3-T4).

In adjusted analyses, the strongest predictor of LOT patients achieving a complete taper was a diagnosis of opioid use disorder: Opioid use disorder patients had 70% higher odds of discontinuation than their counterparts without this diagnosis (aOR = 1.70, 95% CI, 1.05–2.71; Table 3). Non-Hispanic White patients were more likely to be completely tapered relative to patients of other racial/ethnic groups (aOR = 1.61, 95% CI, 1.21– 2.15), and older patients had lower odds of discontinuation than their younger counterparts. Patients with higher levels of medical complexity were significantly less likely to discontinue opioid use

Figure 2. MME reduction among Oregon Medicaid patients with back or neck pain on long-term opioid therapy by starting dose, over 18 months postpolicy implementation



Note: Error bars represent interquartile range MME: morphine milligran equivalence

	Unadjusted or (95% CI)	Adjusted* OR (95% CI
Sex		
Male	Ref	Ref
Female	0.98 (0.81-1.18)	0.93 (0.76-1.14)
Age, years		
19 to 34	Ref	Ref
35 to 49	0.84 (0.59–1.20)	0.91 (0.63-1.30)
50 to 64	0.56 (0.40-0.78)	0.62 (0.43-0.88)
Race/ethnicity		
Hispanic, Black, Indigenous, other patients of color, and unknown race/ethnicity	Ref	Ref
Non-Hispanic White	1.55 (1.17-2.04)	1.61 (1.21–2.15)
Eligible pain diagnoses		
Back pain	Ref	Ref
Neck pain	0.74 (0.55-0.99)	0.73 (0.55-0.99)
Both	1.02 (0.81–1.28)	1.05 (0.83-1.34)
Baseline average daily MME		
<20 MME	Ref	Ref
20 - <50 MME	0.81 (0.65-1.01)	0.81 (0.65-1.01)
50 - <90	0.84 (0.63-1.12)	0.79 (0.59-1.06)
≥90	0.81 (0.60-1.10)	0.75 (0.55-1.04)
Number of visits in the prior year		
<6	Ref	Ref
6 to 9	0.98 (0.76-1.27)	1.02 (0.78-1.32)
10 to 12	1.05 (0.78–1.41)	1.09 (0.81-1.48)
>12	1.14 (0.89–1.48)	1.20 (0.92-1.57)
Charlson Comorbidity Index [†]		
0	Ref	Ref
1 to 2	0.63 (0.48-0.82)	0.64 (0.49-0.85)
≥3	0.60 (0.46-0.80)	0.68 (0.50-0.93)
N pain clusters (of 8) ^{† ‡}		
0	Ref	Ref
1	0.84 (0.65-1.10)	0.87 (0.66-1.14)
≥2	0.82 (0.63-1.05)	0.84 (0.64-1.10)
Alcohol abuse/dependence [†]	1.01 (0.74–1.40)	1.03 (0.74–1.44)
Opioid abuse/dependence [†]	1.64 (1.03-2.59)	1.70 (1.05-2.71)
Other drug abuse/dependence [†]	1.08 (0.82–1.43)	0.98 (0.73-1.32)
Mood disorder ^{† §}	1.08 (0.90–1.31)	1.16 (0.94–1.43)

Table 3. Odds of Reducing Opioid Usage to Zero Among Oregon Medicaid Patients with Back or Neck Pain on Long-Term Opioid Therapy

Abbreviations: OR, odds ratio; MME, morphine milligram equivalence, CI, confidence interval Bold, P < .05. *Model adjusted for all variables in this table.

[†]Conditions based on active problem list entries at baseline.

[‡]Pain conditions assessed: (1) limb/extremity pain, joint pain, and arthritic disorders; (2) neuropathic pain conditions; (3) headache; (4) abdominal and bowel pain; (5) urogenital, pelvic, and menstrual pain; (6) musculoskeletal chest pain; (7) systemic disorders or diseases causing pain; (8) orofacial, ear, and temporomandibular disorder pain. See Appendix Table 1 for definitions.

[§]Includes depression and anxiety disorders. See Appendix Table 1 for definitions.

relative to those with a Charlson score of 0 (Charlson score \geq 3 aOR = 0.68, 95% CI, 0.50–0.93).

Discussion

The rising prevalence of opioid overdose deaths in the U.S. was declared an epidemic in 2011;⁸

especially thereafter, policies were enacted at national, state, and local levels to rein in what was perceived as excessive opioid prescribing.^{9,26,27} The Oregon policy described here was unique in its attempt to align state Medicaid reimbursement policy with best evidence, and aimed to diminish the role of long-term use of opioid medication in treatment of chronic neck and back pain while emphasizing less harmful treatments.

Our cohort of patients had a high level of physical and mental health comorbidity. This is expected in CHCs that are known to serve more complex populations²¹ and especially among a subset of patients with chronic pain. Nor is it unexpected to see lower baseline opioid doses among LOT patients in CHCs compared with those reported in other population descriptions.^{6,14} A previous analysis of opioid prescribing in the OCHIN network in 17 states showed that prescribing per capita decreased from 1,682 MME in 2009 to 243 MME in 2018.28 This was compared with an estimated decrease from 733 MME to 424 in the same years for the entire nation.⁶ In addition, an OHP policy in 2012 required prior authorization for opioid doses over 120 MME/day,²⁹ and a 2015 to 2017 statewide performance improvement program encouraged dosage reduction to below 90 MME daily.30

The Oregon Back and Neck Pain revised guidelines became effective on July 1, 2016. By the target discontinuation date, January 1, 2018, roughly half of the patients in our study cohort were no longer being prescribed opioids. Another 30% were being prescribed less than they had 18 months earlier, and only 20% had maintained or increased their dose. This preponderance of tapering and discontinuation occurred regardless of baseline dose. Even among those whose baseline doses exceeded 90 daily MMEs, nearly half fully discontinued and the majority of the rest tapered to safer doses. Notably, only 6% of this highest-risk group did not decrease their dose at all.

Several studies have explored opioid dose reduction in patient cohorts after interventions. For example, in a cohort of 50 Veterans Administration LOT patients who agreed to be part of a tapering program, 12% fully discontinued opioids, 82% partially tapered, and 6% were on the same or higher dose after 1 year.³¹ Another initiative in an academic medical center clinic was designed to enforce a maximum opioid dose of 120 MME/day. Of the 116 identified patients above this cutoff, 40% were able to taper to less than 120 MMEs/day by the 1year target.³² A third study evaluated a program in a large health care system in which primary care clinicians identified patients they thought would benefit from an intensive tapering program. Of 1,384 patients who consented and were referred, 56% reduced their dose by 50% after 1 year.¹⁴ In light of these studies, our finding that 50% of our cohort fully discontinued opioid use and another 30% partially tapered is noteworthy.

The strength with which the pendulum swung back against using opioids for chronic pain in the 2010s raised concerns that policies aimed at decreasing opioid prescribing could lead to abrupt discontinuation, withdrawal and iatrogenic harm.^{16,17} The CDC Guideline published in 2016 suggested that, once having made the decision to taper, decreases of 10% weekly might be a good starting point, and slower tapers (10% monthly) more appropriate for some. Recent studies have shown that these concerns were indeed warranted, and that tapering often occurs more rapidly than 10% weekly.^{33–35} However this does not seem true of the OHP policy implementation we describe. As seen in Table 2 and Figure 2, those who fully discontinued opioid use tapered over 9 or more months, with those on higher baseline doses taking longer to do so. These data provide compelling evidence that, at least within Oregon CHC settings, tapering and discontinuation did, indeed, occur gradually.

In our cohort, those who discontinued their opioids were more likely to be younger, less medically complex, have a diagnosis of opioid use disorder, and be non-Hispanic White (Table 3). We found no difference by sex, or by the presence of depression or anxiety. Most other studies that characterize patients by likelihood of opioid tapering have found similar association with younger age.^{14,33} Unlike our findings, others have reported that patients are more likely to taper if they are female,^{14,33,36} more medically complex,^{14,33} or Black.^{33,36} Unfortunately, given the relatively small population of Black patients in Oregon and thus, in our Oregon Medicaid cohort, we had insufficient sample size to specifically explore the association of a patient's race or ethnicity with opioid discontinuation. Given well-known racial disparities with regard to pain treatment,37,38 the experience of Black patients with regard to opioid tapering warrants further study.

Our study has a number of limitations. First, our EHR data contains orders for opioid prescriptions initiated from a network of CHCs. It is not possible to determine if these prescriptions were picked up or ingested by patients, nor would our data capture opioid prescriptions obtained from other clinical settings. Second, while all subjects had back or neck pain and were taking LOT, we do not know that the opioid prescriptions were meant specifically to treat their back or neck pain. Third, some patients who seem to have discontinued opioid use may have been misclassified because of not returning for follow-up visits to ascertain further prescribing. Similarly, if patients changed care to a non-OCHIN clinic during the observation period, any subsequent opioid prescribing would be unobserved. However, our sample selection of established patients receiving long-term opioid therapy for at least 6 months in this clinical setting at baseline, and requiring at least 1 visit in the study period, limited the potential effects of this bias. Only about one third of patients did not have any further visits after their last opioid prescription. Our sensitivity analysis excluding these "lost-to-follow-up" patients did not change overall conclusions. Finally, as noted above, there have been many interventions at all levels over the past decade to reduce inappropriate opioid prescribing. We cannot know with certainty how much of the effect we describe in our cohort was due to this specific Oregon Medicaid policy. Yet, given the size of the decline, its consistency among groups, and the stable nature of the clinical population, we believe that at least some component of the opioid discontinuation we have described is due to the policy. This study is part of a larger mixed-methods research project evaluating the policy using a natural experiment design; analysis of other data sets (including California Medicaid data as control group) will help further answer this question.²²

Conclusion

In recent years, efforts to mitigate the harms of LOT in patients and communities required enacting policies with incomplete evidence about potential outcomes.^{7,18,39} Our study shows that, regardless of baseline dose, nearly half of the patients affected by Oregon Medicaid policies concerning treatment of back and neck pain no longer received opioid prescriptions at the end of the study period, while another 30% partially tapered their dose. Moreover, our data show there was very little abrupt discontinuation. Further research is needed to understand the broader impact of such insurance reimbursement policy changes, and especially individual patient experiences and outcomes to help clinicians and policy makers navigate the complex balance between potential harms and potential benefits of chronic opioid therapy.

This work was supported by the Accelerating Data Value Across a National Community Health Center Network (ADVANCE) Clinical Research Network (CRN). OCHIN leads the ADVANCE network in partnership with Health Choice Network, Fenway Health, and Oregon Health & Science University. ADVANCE is funded through the Patient-Centered Outcomes Research Institute (PCORI), contract number RI-CRN-2020-001.

To see this article online, please go to: http://jabfm.org/content/ 35/2/352.full.

References

- Jalal H, Buchanich JM, Roberts MS, Balmert LC, Zhang K, Burke DS. Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016. Science 2018;361.
- 2. Von Korff MR, Franklin G. Responding to America's iatrogenic epidemic of prescription opioid addiction and overdose. Med Care 2016;54:426–9.
- Alpert AE, Evans WN, Lieber EMJ, Powell D. Origins of the opioid crisis and its enduring impacts. National Bureau of Economic Research Working Paper Series. 2019;No. 26500.
- Levy B, Paulozzi L, Mack KA, Jones CM. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012. Am J Prev Med 2015;49:409–13.
- Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. The journal of pain: official journal of the American Pain Society 2006;7:225–35.
- Centers for Disease Control and Prevention. 2019 Annual surveillance report of drug-related risks and outcomes - United States. Surveillance Special Report. 2019. Published November 1, 2019. Accessed December 30, 2019.
- Beaudoin FL, Banerjee GN, Mello MJ. State-level and system-level opioid prescribing policies: the impact on provider practices and overdose deaths, a systematic review. J Opioid Manag 2016;12:109–18.
- Office of National Drug Control Policy. National drug control strategy. 2011. https://obamawhitehouse. archives.gov/sites/default/files/ondcp/ndcs2011.pdf. Accessed January 23, 2020.
- Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain– United States, 2016. JAMA 2016;315:1624–45.
- 10. Oregon Health Authority Health Evidence Review Commission. Coverage guidance: lower back pain: non-pharmacological/non-invasive interventions.

https://www.oregon.gov/oha/HPA/DSI-HERC/ EvidenceBasedReports/Low-Back-Pain-Non-Pharma cologic-Non-Invasive-Interventions-11-13-14.pdf. Published 2014. Accessed November 22, 2020.

- Oregon Health Authority Health Evidence Review Commission. Coverage guidance: lower back pain: pharmacological interventions. https://www.oregon. gov/oha/HPA/DSI-HERC/EvidenceBasedReports/ Low-Back-Pain-Pharmacologic-Interventions-Final-11-13-14.pdf. Published 2014. Accessed November 22, 2020.
- Eaves ER, Hsu CW, DeBar LL, et al. Whole systems within whole systems: the Oregon health plan's expansion of services for back and neck pain. J Altern Complement Med 2019;25:S61– S68.
- Oregon Health Evidence Review Commission. Prioritized list archives. https://www.oregon.gov/ oha/HPA/DSI-HERC/Pages/Prioritized-List-Archives. aspx. Accessed March 7, 2021.
- Kuntz JL, Dickerson JF, Schneider JL, et al. Factors associated with opioid-tapering success: A mixed methods study. J Am Pharm Assoc (2003) 2021;60:248–57.
- Von Korff M, Dublin S, Walker RL, et al. The impact of opioid risk reduction initiatives on highdose opioid prescribing for patients on chronic opioid therapy. J Pain 2016;17:101–10.
- Darnall BD, Juurlink D, Kerns RD, et al. International stakeholder community of pain experts and leaders call for an urgent action on forced opioid tapering. Pain Med 2019;20:429–33.
- 17. Kertesz SG. Outcomes after opioid dose reductions and stoppage: it's time to start counting. J Subst Abuse Treat 2019;103:64–5.
- Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med 2019; 380:2285–7.
- U.S. Department of Health and Human Services. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. https://www.cms. gov/About-CMS/Story-Page/CDCs-Tapering-Guidance.pdf. Published 2019. AS12,2.
- Centers for Disease Control and Prevention. Pocket guide: tapering opioids for chronic pain. https:// www.cdc.gov/drugoverdose/pdf/clinical_pocket_ guide_tapering-a.pdf.
- National Association of Community Health Centers. Community health center chartbook 2019. http://www.nachc.org/wp-content/uploads/2019/ 01/Community-Health-Center-Chartbook-FINAL-1.28.19.pdf.
- 22. U.S. National Library of Medicine Clinical Trials.gov. A Naturalistic Experiment Evaluating the Impact of Medicaid Treatment Reimbursement Changes on Opioid Prescribing and Patient

Outcomes Among Patients With Back Pain (Back on Track). https://clinicaltrials.gov/ct2/show/NCT03393143.

- Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008;61:1234–40.
- 24. Mayhew M, DeBar LL, Deyo RA, et al. Development and assessment of a crosswalk between ICD-9-CM and ICD-10-CM to identify patients with common pain conditions. J Pain 2019;20:1429–45.
- Centers for Disease Control and Prevention. Data resources - oral MMEs. 2018. https://www.cdc.gov/ drugoverdose/resources/data.html.
- 26. Wen H, Schackman BR, Aden B, Bao Y. States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees. Health Aff (Millwood) 2017;36:733–41.
- Mauri AI, Townsend TN, Haffajee RL. The Association of State Opioid Misuse Prevention Policies with patient- and provider-related outcomes: a scoping review. Milbank Q 2020;98:57– 105.
- Muench J, Fankhauser K, Voss RW, et al. Assessment of opioid prescribing patterns in a large network of US community health centers, 2009 to 2018. JAMA Netw Open 2020;3: e2013431.
- 29. Hartung DM, Kim H, Ahmed SM, et al. Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes. Subst Abus 2018;39:239–46.
- Oregon Health Authority Office of Delivery Systems Innovation. Statewide Performance Improvement Project. https://www.oregon.gov/oha/HPA/DSI/ pages/Performance-Improvement-Project.aspx. Published 2019. AS12,2.
- Harden P, Ahmed S, Ang K, Wiedemer N. Clinical Implications of Tapering Chronic Opioids in a Veteran Population. Pain Med 2015;16:1975–81.
- Weimer MB, Hartung DM, Ahmed S, Nicolaidis C. A chronic opioid therapy dose reduction policy in primary care. Subst Abus 2016;37:141–7.
- Fenton JJ, Agnoli AL, Xing G, et al. Trends and rapidity of dose tapering among patients prescribed long-term opioid therapy, 2008-2017. JAMA Netw Open 2019;2:e1916271.
- Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abuse Treat 2019;103:58–63.
- 35. Ranapurwala SI, Ringwalt CL, Pence BW, et al. State medical board policy and opioid prescribing: a controlled interrupted time series. Am J Prev Med 2020;60:343–51.
- 36. Buonora M, Perez HR, Heo M, Cunningham CO, Starrels JL. Race and gender are associated

with opioid dose reduction among patients on chronic opioid therapy. Pain medicine 2019;20: 1519–27.

- Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008;299:70–8.
- 38. Singhal A, Tien YY, Hsia RY. Racial-ethnic disparities in opioid prescriptions at emergency

department visits for conditions commonly associated with prescription drug abuse. PLoS One 2016;11:e0159224.

 Chou R, Ballantyne JC, Fanciullo GJ, Fine PG, Miaskowski C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009;10:147–59.

Appendix

Appendix Ta	ble 1. Con	ndition D	efinitions
-------------	------------	-----------	------------

	Icd-10-CM
Back pain	G54.1, G54.3, G54.4, G96.11, L40.53, M08.1, M25.78, M43.00, M43.04, M43.05, M43.06, M43.07, M43.08, M43.09, M43.10, M43.14, M43.15, M43.16, M43.17, M43.18, M43.19, M43.5 × 4, M43.5 × 5, M43.5 × 6, M43.5 × 7, M43.5 × 8, M43.5 × 9, M43.8 × 4, M43.8 × 5, M43.8 × 6, M43.8 × 7, M43.8 × 9, M45.0, M45.4, M45.5, M45.6, M45.7, M45.8, M45.9, M46.00, M46.00, M46.04, M46.05, M46.00, M46.07, M46.08, M46.09, M46.1, M46.40, M46.45, M46.45, M46.46, M46.47, M46.48, M46.49, M46.80, M46.81, M46.89, M46.89, M46.90, M46.1, M46.40, M46.40, M46.67, M46.09, M46.1, M46.40, M46.41, M47.14, M47.15, M47.16, M47.20, M47.24, M47.25, M47.26, M47.27, M47.28, M47.10, M47.14, M47.15, M47.16, M47.27, M47.25, M47.26, M47.27, M47.28, M47.897, M47.898, M47.899, M47.9, M48.00, M48.04, M48.05, M48.07, M48.08, M48.25, M48.26, M48.14, M48.15, M48.16, M48.35, M48.18, M48.19, M48.20, M48.24, M48.25, M48.26, M48.27, M48.30, M48.34, M48.35, M48.36, M48.37, M48.38, M48.8 × 4, M48.8 × 5, M48.8 × 6, M48.8 × 7, M48.8 × 8, M48.8 × 9, M48.9, M49.84, M49.84, M49.85, M49.86, M49.87, M49.88, M49.89, M51.04, M51.105, M51.16, M51.17, M51.24, M51.25, M51.26, M51.27, M51.34, M51.35, M51.36, M51.37, M51.44, M51.45, M51.26, M51.27, M51.34, M51.35, M51.36, M51.37, M51.44, M51.45, M51.45, M51.45, M51.46, M51.47, M51.48, M51.85, M51.86, M51.87, M51.9, M53.2 × 4, M53.2 × 5, M53.2 × 6, M53.2 × 7, M53.2 × 8, M53.2 × 9, M53.3, M53.80, M53.84, M53.86, M53.87, M53.88, M53.99, M54.00, M54.01, M99.02, M99.03, M99.04, M99.05, M99.12, M99.14, M99.18, M99.53, M99.53, M99.73, M99.79, M99.82, M99.83, M99.84, M99.85, M99.88, Q67.5, Q76.0, Q76.1, Q76.2, Q76.31, Q76.414, Q76.415, Q76.419, Q76.49, Q33.101, S33.101, S33.101 Ass, S33.111 Ass, S33.111 Days, S33.111 Second, S33.1143, S33.113 Days, S23.1131, S23.121 Days, S23.131 Second, S23.20XA, S33.20XD, S33.20XD, S33.20XD, S33.20XD, S33.20XD, S33.20XD, S33.20XD, S33.20XD, S33.
Neck pain	G54.2, M43.01, M43.02, M43.03, M43.11, M43.12, M43.13, M43.3, M43.4, M43.5 × 2, M43.5 × 3, M43.6, M43.8 × 1, M43.8 × 2, M43.8 × 3, M45.1, M45.2, M45.3, M46.01, M46.02, M46.03, M46.41, M46.42, M46.43, M46.81, M46.82, M46.83, M46.91, M46.92, M46.93, M47.11, M47.12, M47.13, M47.22, M47.811, M47.812, M47.813, M47.891, M47.892, M47.893, M48.01, M48.02, M48.03, M48.11, M48.12, M48.13, M48.21, M48.22, M48.33, M48.31, M48.32, M48.33, M48.8 × 1, M48.8 × 2, M48.8 × 3, M49.81, M49.82, M49.83, M50.00, M50.01, M50.020, M50.021, M50.022, M50.023, M50.03, M50.10, M50.11, M50.120, M50.121, M50.020, M50.021, M50.020, M50.21, M50.220, M50.221, M50.221, M50.223, M50.30, M50.31, M50.30, M50.31, M50.321, M50.322, M50.323, M50.33, M50.80, M50.81, M50.820, M50.821, M50.822, M50.823, M50.83, M50.90, M50.91, M50.920, M50.921, M50.922, M50.923, M50.93, M53.0, M53.1, M53.2 × 1, M53.2 × 2, M53.2 × 3, M53.81, M53.82, M53.83, M54.01, M54.02, M54.03, M54.11, M54.12, M54.13, M54.2, M95.3, M99.01, M99.11, M99.31, M99.51, M99.61, M99.71, M99.81, Q76.411, Q76.412, Q76.413, S13.0XXA, S13.100A, S13.100 Days, S13.101 A, S13.111 Days, S13.111 Days, S13.111 Second, S13.120A, S13.121A, S13.121 Days, S13.121 Second, S13.130A, S13.131A, S13.151 A, S13.151 Days, S13.151 Second, S13.160A, S13.160 Days, S13.161 A, S13.161 Days, S13.161 Second, S13.170 Days, S13.171 A, S13.171 Days, S13.171 Second, S13.180A, S13.181A, S13.181 Days, S13.181 Second, S13.20XX, S13.20XX, S13.20XX, S13.20XX, S13.29XX, S13.29XX, S13.29XX, S13.40X, S13.40X, S13.40X, S13.40X, S13.40X, S13.411 Days, S13.1180A, S13.414, S13.421 Days, S13.161 Days, S13.161 Days, S13.171 Days, S13.171 Second, S13.180A, S13.181A, S13.181 Days, S13.181 Second, S13.20XX, S13.20XX, S13.29XX, S13.29XX, S13.9XXD, S13.9XXD, S13.4XXA, S13.4XXD, S13.4XXS, S13.5XXA, S13.8XXA, S13.8XXD, S13.8XXS, S13.9XXD,

	Icd-10-CM
Limb/extremity pain, joint pain, and arthritic disorders	A52.16, G54.0, G54.6, G56.00, G56.01, G56.02, G56.03, G56.40, G56.41, G56.42, G56.43, G57.20, G57.10, G57.02, G57.00, G57.10, G57.11, G57.22, G57.33, G57.30, G57.31, G57.32, G57.33, G57.33, G57.30, G57.71, G57.70, G57.71, G57.72, G57.73, G72.9, T7.6, M02.00, M02.01, M02.012, M02.019, M02.021, M02.022, M02.029, M02.031, M02.062, M02.040, M02.044, M02.049, M02.049, M02.049, M02.049, M02.049, M02.049, M02.049, M02.049, M02.049, M02.051, M02.052, M02.059, M02.061, M02.062, M02.062, M02.061, M07.661, M07.671, M00.072, M10.029, M10.001, M10.021, M10.024, M10.049, M10.041, M10.041, M10.042, M10.049, M10.061, M10.021, M10.022, M10.039, M10.330, M10.331, M10.332, M10.339, M10.331, M10.339, M10.331, M10.322, M10.339, M10.331, M10.322, M10.339, M10.331, M10.332, M10.339, M10.331, M10.339, M10.331, M10.342, M10.449, M10.441, M10.442, M10.449, M10.441, M10.442, M10.449, M10.451, M10.442, M10.449, M11.451, M11.420, M11.261, M11.262, M11.263, M11.26

Icd-10-CM
M24.241, M24.242, M24.249, M24.251, M24.252, M24.259, M24.271, M24.272, M24.273, M24.274, M24.275, M24.276, M24.28, M24.40, M24.411, M24.412, M24.419, M24.421, M24.422, M24.429, M24.431, M24.432, M24.439, M24.441, M24.442, M24.443, M24.444, M24.445, M24.446, M24.451, M24.452, M24.459, M24.461, M24.462, M24.469, M24.471, M24.472, M24.473, M24.474, M24.475, M24.476, M24.477, M24.478, M24.479, M24.50, M24.511, M24.512, M24.519, M24.521, M24.522, M24.529, M24.531, M24.532, M24.539, M24.541, M24.542, M24.542, M24.549, M24.551, M24.552, M24.559, M24.561, M24.562, M24.569, M24.571, M24.572, M24.573, M24.574, M24.575, M24.576, M24.60, M24.611, M24.612, M24.619, M24.621, M24.622, M24.639, M24.661, M24.662, M24.669, M24.671, M24.672, M24.649, M24.651, M24.652, M24.659, M24.661, M24.662, M24.669, M24.671, M24.672,
M24.673, M24.674, M24.675, M24.676, M24.7, M25.50, M25.511, M25.512, M25.519, M25.521, M25.522, M25.529, M25.531, M25.532, M25.539, M25.541, M25.542, M25.549, M25.551, M25.552, M25.559, M25.561, M25.562, M25.569, M25.571, M25.572, M25.579, M25.70, M25.711, M25.712, M25.719, M25.721, M25.722, M25.729, M25.731, M25.732, M25.739, M25.741, M25.742, M25.749, M25.751, M25.752, M25.759, M25.761, M25.762, M25.769, M25.771, M25.772, M25.773, M25.774, M25.775, M25.776, M35.4, M62.40, M62.411, M62.412, M62.419, M62.421, M62.422, M62.429, M62.431, M62.432, M62.439, M62.441, M62.442, M62.449, M62.451, M62.452, M62.459, M62.461, M62.462, M62.469, M62.471, M62.472, M62.479, M62.48, M62.49, M62.831, M62.838, M62.89, M65.00, M65.011, M65.012, M65.001, M65.021, M65.022, M65.029, M65.031, M65.032, M65.039, M65.041, M65.0
M65.042, M65.049, M65.051, M65.052, M65.059, M65.061, M65.062, M65.069, M65.071, M65.072, M65.079, M65.08, M65.10, M65.161, M65.20, M65.221, M65.222, M65.229, M65.231, M65.232, M65.239, M65.241, M65.242, M65.249, M65.251, M65.252, M65.259, M65.261, M65.262, M65.269, M65.271, M65.272, M65.279, M65.311, M65.312, M65.319, M65.321, M65.322, M65.329, M65.331, M65.332, M65.339, M65.341, M65.342, M65.349, M65.351, M65.352, M65.859, M65.831, M65.832, M65.80, M65.811, M65.842, M65.841, M65.842, M65.841, M65.842, M65.851, M65.852, M65.859, M65.861, M65.832, M65.869, M65.871, M65.872, M65.879, M65.871, M65.872, M65.879, M65.871, M66.272, M66.279, M66.284, M66.290, M66.211, M66.212, M66.221, M66.222, M66.222, M66.231, M66.232, M66.239, M66.241, M66.242, M66.249, M66.251, M66.252, M66.252, M66.262, M66.262, M66.271, M66.272, M66.279, M66.28,
M66.29, M66.30, M66.311, M66.312, M66.319, M66.321, M66.322, M66.329, M66.331, M66.332, M66.339, M66.341, M66.342, M66.349, M66.351, M66.352, M66.359, M66.361, M66.362, M66.369, M66.371, M66.372, M66.379, M66.38, M66.39, M66.80, M66.811, M66.812, M66.819, M66.821, M66.822, M66.829, M66.831, M66.832, M66.839, M66.841, M66.842, M66.849, M66.851, M66.852, M66.859, M66.861, M66.862, M66.864, M66.871, M66.872, M66.879, M66.88, M66.89, M67.00, M67.01, M67.02, M67.311, M67.322, M67.331, M67.332, M67.311, M67.351, M67.352, M67.371, M67.812, M67.819, M67.819, M67.821, M67.822, M67.823, M67.824, M67.829, M67.831, M67.832, M67.833, M67.834, M67.839, M67.841, M67.842, M67.844, M67.849, M67.851, M67.852, M67.853, M67.854, M67.859, M67.844, M67.849, M67.851, M67.852, M67.853, M67.854, M67.859, M67.844, M67.844, M67.844, M67.845, M67.851, M67.852, M67.853, M67.854, M67.859, M67.844, M67.844, M67.844, M67.851, M67.852, M67.853, M67.854, M67.859, M67.844, M67.844, M67.844, M67.844, M67.845, M67.851, M67.852, M67.853, M67.854, M67.859, M67.851, M67.852, M67.853, M67.854, M67.859, M67.851, M67.851, M67.852, M67.853, M67.854, M67.859, M67.851, M67.852, M67.853, M67.854, M67.859, M67.844, M67.844, M67.844, M67.844, M67.851, M67.852, M67.853, M67.854, M67.859, M67.844, M67.844, M67.844, M67.844, M67.844, M67.844, M67.845, M67.851, M67.852, M67.853, M67.854, M67.859, M67.854, M67.
M67.861, M67.862, M67.863, M67.864, M67.869, M67.871, M67.872, M67.873, M67.874, M67.879, M67.888, M67.89, M67.90, M67.911, M67.912, M67.919, M67.921, M67.922, M67.929, M67.931, M67.932, M67.939, M67.941, M67.942, M67.949, M67.951, M67.952, M67.959, M67.961, M67.962, M67.969, M67.971, M67.972, M67.979, M67.98, M67.99, M70.031, M70.032, M70.039, M70.10, M70.11, M70.12, M70.20, M70.21, M70.22, M70.30, M70.31, M70.32, M70.40, M70.41, M70.42, M70.50, M70.51, M70.52, M70.60, M70.61, M70.62, M70.70, M70.71, M70.72, M70.90, M71.011, M71.012, M71.012, M71.019, M71.021, M71.022, M71.029, M71.031, M71.032, M71.039, M71.039, M71.041, M71.042, M71.049, M71.051, M71.052, M71.059, M71.061, M71.122, M71.106, M71.161, M71.162, M71.20, M71.21, M71.22, M71.319, M71.321, M71.322, M71.329, M71.331, M71.332,
M71.339, M71.341, M71.342, M71.349, M71.351, M71.352, M71.359, M71.371, M71.372, M71.379, M71.381, M71.39, M71.40, M71.40, M71.421, M71.422, M71.429, M71.431, M71.432, M71.439, M71.441, M71.442, M71.449, M71.451, M71.452, M71.459, M71.461, M71.462, M71.469, M71.471, M71.472, M71.479, M71.48, M71.49, M71.50, M71.521, M71.522, M71.529, M71.531, M71.532, M71.539, M71.541, M71.542, M71.549, M71.551, M71.552, M71.559, M71.561, M71.562, M71.569, M71.571, M71.572, M71.579, M71.58, M71.80, M71.811, M71.812, M71.819, M71.821, M71.822, M71.829, M71.831, M71.832, M71.839, M71.841, M71.842, M71.849, M71.852, M71.859, M71.861, M71.862, M71.869, M71.871, M71.872, M71.879, M71.881, M71.89, M71.9, M72.2, M75.00, M75.01, M75.02, M75.100, M75.101, M75.102, M75.111, M75.112, M75.40, M75.41, M75.42, M75.40, M75.41, M75.42, M75.50, M75.51, M75.52, M75.52, M75.52, M76.21, M76.22, M76.30, M76.40, M76.41, M76.42, M76.50, M76.51, M76.52,
M76.60, M76.61, M76.62, M76.70, M76.71, M76.72, M76.811, M76.812, M76.819, M76.821,

	Icd-10-CM
	$ \begin{array}{l} M76.822, M76.829, M76.891, M76.892, M76.899, M77.00, M77.01, M77.02, M77.10, M77.11, \\ M77.12, M77.20, M77.21, M77.22, M77.30, M77.31, M77.32, M77.40, M77.41, M77.42, \\ M77.50, M77.51, M77.52, M77.8, M77.9, M79.601, M79.602, M79.603, M79.604, M79.605, \\ M79.606, M79.609, M79.621, M79.622, M79.629, M79.631, M79.632, M79.639, M79.641, \\ M79.642, M79.643, M79.644, M79.645, M79.646, M79.651, M79.652, M79.659, M79.661, \\ M79.662, M79.669, M79.671, M79.672, M79.673, M79.674, M79.675, M79.676, M89.30, \\ M89.311, M89.312, M89.319, M89.321, M89.322, M89.329, M89.331, M89.332, M89.333, \\ M89.334, M89.339, M89.341, M89.342, M89.349, M89.351, M89.352, M89.359, M89.361, \\ M89.362, M89.63, M89.364, M89.369, M89.571, M89.522, M89.529, M89.531, M89.532, \\ M89.50, M89.511, M89.512, M89.519, M89.521, M89.522, M89.529, M89.531, M89.532, \\ M89.569, M89.571, M89.572, M89.579, M89.58, M89.59, M89.8 \times 0, M89.8 \times 1, M89.8 \times 2, \\ M89.8 \times 3, M89.8 \times 4, M89.8 \times 5, M89.8 \times 6, M89.8 \times 7, M89.8 \times 8, M89.8 \times 9, M89.9, \\ M94.8 \times 4, M94.8 \times 5, M94.8 \times 6, M94.8 \times 7, M94.8 \times 8, M94.8 \times 9, M94.9, M99.06, M99.07, \\ Q66.89, Q74.9, R25.2 \\ \end{array}$
Neuropathic pain	B02.22, B02.23, E08.42, E10.40, E10.41, E10.42, E10.43, E10.610, E11.40, E11.42, E11.43, E11.610, E13.40, E13.41, E13.42, E13.43, G50.0, G50.8, G50.9, G52.1, G54.8, G54.9, G56.80, G56.81, G56.82, G56.83, G56.90, G56.91, G56.92, G56.93, G57.80, G57.81, G57.82, G57.83, G57.90, G57.91, G57.92, G57.93, G58.7, G58.8, G58.9, G59, G60.2, G60.3, G60.8, G60.9, G61.9, G62.0, G62.89, G62.9, G63, G90.09, G99.0, H46.2, H46.3, H46.8, H46.9, H47.011, H47.012, H47.013, H47.019, M79.2
Headache	G43.001, G43.009, G43.011, G43.019, G43.101, G43.109, G43.109A, G43.111, G43.119, G43.401, G43.409, G43.411, G43.419, G43.501, G43.509, G43.511, G43.519, G43.601, G43.609, G43.611, G43.619, G43.701, G43.709, G43.711, G43.719, G43.801, G43.809, G43.811, G43.819, G43.821, G43.829, G43.831, G43.839, G43.901, G43.909, G43.911, G43.919, G43.80, G43.81, G43.81, G43.C0, G43.C1, G44.001, G44.009, G44.011, G44.019, G44.021, G44.029, G44.039, G44.049, G44.051, G44.059, G44.09, G44.1, G44.201, G44.209, G44.211, G44.219, G44.221, G44.229, G44.300, G44.311, G44.319, G44.321, G44.329, G44.51, G44.52, G44.53, G44.59, G44.81, G44.82, G44.83, G44.84, G44.85, G44.89, M54.81, R51
Abdominal and bowel pain	G43.D0, G43.D1, K40.00, K40.01, K40.20, K40.21, K40.30, K40.31, K40.90, K40.91, K41.00, K41.01, K41.30, K41.31, K41.90, K41.91, K42.0, K42.9, K43.0, K43.2, K43.3, K43.5, K43.6, K43.9, K44.0, K44.9, K45.0, K45.8, K46.0, K46.9, K58.0, K58.1, K58.2, K58.8, K58.9, K80.00, K80.01, K80.10, K80.11, K80.12, K80.13, K80.18, K80.19, K80.20, K80.21, K80.30, K80.31, K80.32, K80.33, K80.34, K80.35, K80.36, K80.37, K80.40, K80.41, K80.42, K80.43, K80.44, K80.45, K80.46, K80.47, K80.50, K80.51, K80.60, K80.61, K80.62, K80.63, K80.64, K80.65, K80.66, K80.67, K80.70, K80.71, M99.09, N20.0, N20.1, N20.2, R10.10, R10.11, R10.12, R10.13, R10.30, R10.31, R10.32, R10.33, R10.84, R10.9
Urogenital, pelvic, and menstrual pain	A54.22, A59.02, N20.9, N21.0, N21.1, N21.8, N21.9, N22, N30.10, N30.11, N41.0, N41.1, N41.9, N42.0, N45.1, N50.811, N50.812, N50.819, N50.82, N50.89, N50.9, N51, N53.12, N71.0, N71.1, N71.9, N72, N73.0, N73.1, N73.2, N73.3, N73.4, N73.5, N73.8, N73.9, N80.0, N80.1, N80.2, N80.3, N80.4, N80.5, N80.6, N80.8, N80.9, N94.0, N94.10, N94.11, N94.12, N94.19, N94.2, N94.3, N94.4, N94.5, N94.6, N94.810, N94.818, N94.819, N94.89, R10.2
Musculoskeletal chest pain	G58.0, I20.0, I20.1, I20.8, I20.9, M94.0, M99.08, R07.1, R07.2, R07.81, R07.82, R07.89, R07.9, S23.41XA, S23.41XD, S23.41XS, S23.420A, S23.420 Days, S23.420S, S23.421A, S23.421 Days, S23.421 Second, S23.428A, S43.206A, S43.214A, S43.214 Days, S43.214S, S43.215A, S43.215 Days, S43.215S, S43.216A, S43.216 Days, S43.216S
Systemic disorders or diseases causing pain	 A69.20, D57.1, D57.20, D57.219, D57.3, D57.40, D57.419, D57.80, D57.819, G90.50, G90.511, G90.512, G90.513, G90.519, G90.521, G90.522, G90.523, G90.529, G90.59, M02.30, M02.311, M02.312, M02.319, M02.321, M02.322, M02.329, M02.331, M02.332, M02.339, M02.341, M02.342, M02.349, M02.351, M02.352, M02.359, M02.361, M02.362, M02.369, M02.371, M02.372, M02.379, M02.38, M02.39, M05.00, M05.011, M05.012, M05.019, M05.021, M05.022, M05.029, M05.031, M05.032, M05.039, M05.041, M05.042, M05.049, M05.051, M05.052, M05.059, M05.061, M05.062, M05.069, M05.071, M05.072, M05.079, M05.09, M05.101, M05.112, M05.112, M05.121, M05.122, M05.129, M05.131, M05.132, M05.139, M05.141, M05.142, M05.149, M05.151, M05.152, M05.20, M05.211, M05.221, M05.222, M05.229, M05.231, M05.232, M05.239, M05.241, M05.242, M05.249, M05.251, M05.252, M05.359, M05.261, M05.269, M05.271, M05.272, M05.279, M05.29, M05.311, M05.312, M05.321, M05.322, M05.329, M05.331, M05.332, M05.339, M05.341, M05.342, M05.351, M05.352, M05.359, M05.361, M05.424, M05.441, M05.442, M05.4449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.441, M05.442, M05.4449, M05.4451, M05.4452, M05.461, M05.462, M05.469, M05.471, M05.472, M05.472, M05.449, M05.4449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.472, M05.472, M05.471, M05.472, M05.449, M05.4451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.449, M05.4451, M05.4452, M05.461, M05.462, M05.469, M05.471, M05.472, M05.449, M05.4449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.449, M05.4451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.449, M05.4459, M05.451, M05.459, M05.461, M05.462,

	Icd-10-CM
	 M05.479, M05.49, M05.50, M05.511, M05.512, M05.519, M05.521, M05.522, M05.529, M05.531, M05.532, M05.539, M05.541, M05.512, M05.551, M05.552, M05.559, M05.561, M05.562, M05.560, M05.571, M05.622, M05.631, M05.632, M05.60, M05.611, M05.612, M05.649, M05.651, M05.652, M05.659, M05.661, M05.662, M05.669, M05.671, M05.672, M05.721, M05.721, M05.722, M05.720, M05.69, M05.70, M05.711, M05.712, M05.711, M05.721, M05.722, M05.720, M05.761, M05.672, M05.69, M05.70, M05.701, M05.714, M05.772, M05.771, M05.720, M05.701, M05.761, M05.762, M05.761, M05.741, M05.772, M05.779, M05.731, M05.780, M05.731, M05.771, M05.772, M05.779, M05.80, M05.80, M05.811, M05.842, M05.849, M05.851, M05.852, M05.859, M05.861, M05.862, M05.80, M05.871, M05.842, M05.849, M05.851, M05.852, M05.859, M05.861, M05.862, M05.80, M05.871, M05.872, M06.787, M05.79, M06.041, M06.042, M06.019, M06.021, M06.022, M06.031, M06.032, M06.639, M06.011, M06.042, M06.049, M06.051, M06.052, M06.654, M06.860, M06.811, M06.821, M06.822, M06.829, M06.881, M06.852, M06.864, M06.864, M06.864, M06.871, M06.872, M06.871, M06.852, M06.889, M06.89, M06.89, M06.811, M06.862, M06.881, M06.852, M06.889, M06.89, M08.011, M08.021, M08.021, M08.021, M08.022, M08.031, M08.032, M08.039, M08.041, M08.042, M08.049, M08.051, M08.052, M08.203, M08.031, M08.062, M08.201, M08.221, M08.231, M08.232, M08.331, M08.441, M08.442, M08.441, M08.442, M08.441, M08.442, M08.451, M08.451, M08.821, M08.821, M08.821, M08.821, M08.822, M08.841, M08.841, M08.442, M08.449, M08.451, M08.821, M08.821, M08.221, M08.252, M08.851, M08.852, M08.851, M08.852, M08.851, M08.822, M08.851, M08.822, M08.841, M08.842, M08.851, M08.851, M08.852, M08.851, M08.852, M08.851, M08.8
Orofacial, ear, and temporomandibular disorder pain	M72.9, M79.0 G50.1, H57.10, H57.11, H57.12, H57.13, M26.51, M26.52, M26.601, M26.602, M26.603, M26.609, M26.611, M26.612, M26.613, M26.619, M26.621, M26.622, M26.623, M26.629, M26.631, M26.632, M26.633, M26.639, M26.69, M27.0, M27.2, M27.8, M27.9, M99.00, R68.84, S03.00XA, S03.00XD, S03.00XS, S03.01XA, S03.01XD, S03.01XS, S03.02XA, S03.02XD, S03.02XS, S03.03XA, S03.03XD, S03.03XS, S03.40XA, S03.40XD, S03.40XS, S03.41XA, S03.41XD, S03.41XS, S03.42XA, S03.42XD, S03.42XS, S03.43XA, S03.43XD, S03.43XS, S03.4XXA
Alcohol abuse/ dependence	F10%, G62.1, K70%
Opioid abuse/ dependence	F11%
Other drug abuse/ dependence	F12%, F13%, F14%, F15%, F16%, F18%, F19%
Mood disorders	F06.4, F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.9, F33.0, F33.1, F33.2, F33.3, F33.40, F33.41, F33.42, F33.9, F34.1, F40.00, F40.01, F40.02, F40.10, F40.11, F40.210, F40.218, F40.220, F40.228, F40.230, F40.231, F40.232, F40.233, F40.240, F40.241, F40.242, F40.243, F40.248, F40.290, F40.291, F40.298, F40.8, F40.9, F41.0, F41.1, F41.3, F41.8, F41.9, F42, F43.0, F43.10, F43.11, F43.12, F43.21, F48.8, F48.9, R45.2, R45.5, R45.6, R45.7

	Average daily dose at end of follow-up				
	0 MME N = 889	1 to <20 MME N = 415	20 to <50 MME N = 287	50 to <90 MME N = 133	≥90 MME N = 65
Mean annual visit rate (SD)	7.2 (16.5)	9.8 (8.5)	9.8 (5.8)	10.4 (11.9)	11.9 (9.3)
Median annual visit rate (IQR)	4.7 (2.0, 8.0)	7.3 (4.7, 12.0)	8.0 (5.3, 12.7)	8.0 (5.3, 12.7)	9.3 (6.7, 14.7)
Number of visits after last opioid prescription, n (%)					
0	324 (36.4%)				
1	135 (15.2%)				
2 to 4	221 (24.9%)				
≥5	209 (23.5%)				
Mean (SD) number of visits after last opioid prescription	3.9 (7.9)				
Mean (SD) number of days between last opioid prescription and last visit, among those with further visit(s)	217.7 (167.7)				

Appendix Table 2. CHC Utilization during 18-Month Study Follow-Up Period by Ending MME Dose

Abbreviations: MME, morphine milligram equivalence; SD, standard deviation; IQR, interquartile range.

	Full sample n (%) N = 1,789	Sensitivity sample n (%) N = 1,465
Sex		
Female	1083 (60.5)	893 (61.0)
Age, years	× ,	
Mean (SD)	49.2 (9.2)	49.4 (11.9)
19 to 34	163 (9.1)	129 (8.8)
35 to 49	593 (33.2)	473 (32.3)
50 to 64	1033 (57.7)	863 (58.9)
Race/ethnicity		
Non-Hispanic White	1556 (87.0)	1256 (85.7)
Hispanic, Black, Indigenous, other patients of color, and unknown race/ethnicity	233 (13.0)	209 (14.3)
Eligible pain diagnoses		
Back pain	1183 (66.1)	964 (65.8)
Neck pain	223 (12.5)	196 (13.4)
Both	383 (21.4)	305 (20.8)
Average daily MME		
<20	745 (41.6)	634 (43.3)
20 to <50	578 (32.3)	473 (32.3)
50 to <90	259 (14.5)	200 (13.7)
≥90	207 (11.6)	158 (10.8)
Number of visits in the prior year		
Median (IQR)	9.0 (6.0, 14.0)	9.0 (6.0, 14.0)
<6	422 (23.6)	326 (22.3)
6 to 9	523 (29.2)	431 (29.4)
10 to 12	305 (17.1)	243 (16.6)
>12	539 (30.1)	465 (31.7)
Charlson Comorbidity Index*		
0	309 (17.3)	232 (15.8)
1 to 2	899 (50.3)	730 (49.8)
≥3	581 (32.5)	503 (34.3)
N pain clusters (of 8)* †		
0	338 (18.9)	262 (17.9)
1	638 (35.7)	531 (36.3)
≥2	813 (45.4)	672 (45.9)
Alcohol abuse/dependence*	164 (9.2)	132 (9.0)
Opioid abuse/dependence*	80 (4.5)	60 (4.1)
Other drug abuse/dependence*	224 (12.5)	195 (13.3)
Mood disorder* ‡	1098 (61.4)	905 (61.8)

Appendix Table 3. Baseline Characteristics, Full Sample, and Sensitivity Sample Excluding Complete Discontinuation Patients with No Further Clinic Visit Following Last Opioid Prescription

Abbreviations: SD, standard deviation; MME, morphine milligram equivalence; IQR, interquartile range. *Conditions based on active problem list entries at baseline.

[†]Pain conditions assessed: (1) limb/extremity pain, joint pain, and arthritic disorders; (2) neuropathic pain conditions; (3) headache; (4) abdominal and bowel pain; (5) urogenital, pelvic, and menstrual pain; (6) musculoskeletal chest pain; (7) systemic disorders or diseases causing pain; (8) orofacial, ear, and temporomandibular disorder pain. See Appendix Table 2 for definitions.

⁺Includes depression and anxiety disorders. See Appendix Table 2 for definitions.

		Average daily dose at baseline			
	Total N = 1,465 n (column %)	<20 MME N = 634 column %	20 to < 50 MME N = 473 column %	50 to <90 MME N = 200 column %	≥90 MME N = 158 column %
Opioid reduction measures at end of follow- up					
Reduced to 0 MME	565 (38.6%)	44.3%	35.7%	33.0%	31.0%
Mean (SD) number of calendar quarters to reduce to zero MME	3.0 (1.7)	2.7 (1.6)	3.1 (1.7)	3.6 (1.7)	3.9 (1.6)
Partially reduced MME	536 (36.6%)	28.2%	38.1%	40.5%	60.8%
Mean (SD) MME at end of follow-up, among patients with partial reduction	28.0 (33.5)	7.4 (4.5)	18.9 (10.1)	36.3 (18.9)	76.4 (49.1)
Did not reduce MME	364 (24.9%)	27.4%	26.2%	26.5%	8.2%
Average daily dose at end of follow-up					
0 MME	565 (38.6%)	44.3%	35.7%	33.0%	31.0%
1 to <20 MME	415 (28.3%)	46.4%	19.7%	10.0%	5.1%
20 to <50 MME	287 (19.6%)	7.7%	38.1%	18.0%	13.9%
50 to <90 MME	133 (9.1%)	1.3%	6.1%	30.5%	22.2%
≥90 MME	65 (4.4%)	<1%	<1%	8.5%	27.9%

Appendix Table 4. Opioid Reduction Outcomes, Sensitivity Sample Excluding Complete Discontinuation Patients with No Further Clinic Visit Following Last Opioid Prescription

Abbreviation: MME, morphine milligram equivalence.

Patient Ns have been suppressed in this table due to some small cell sizes.